Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04145128 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants
A Phase 1 study, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04145128 is a Phase 1 study that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT04145128, a Phase 1 study, has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the pharmacokinetics (PK) and safety of AG-881 in healthy Japanese and Non-Asian participants after single oral doses of 10 mg and 50 mg of AG-881.
Interventions
- DRUG AG881
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-10-02 |
| Est. Completion | 2019-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04145128
The ClinicalTrials.gov registry entry for NCT04145128 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG881 is the first listed.
NCT04145128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04145128 about?
NCT04145128 is a clinical study titled "A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants". The purpose of this study is to compare the pharmacokinetics (PK) and safety of AG-881 in healthy Japanese and Non-Asian participants after single oral doses of 10 mg and 50 mg of AG-881.
What is the current status of trial NCT04145128?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2019-10-02. Estimated completion is 2019-12-18.
What interventions are being tested in trial NCT04145128?
The interventions under investigation include: AG881 (DRUG).
Who is sponsoring clinical trial NCT04145128?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.